DRG Epidemiology’s coverage of achromatopsia (ACHM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of ACHM for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s ACHM forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACHM over the forecast period?
  • How many cases of ACHM are due to specific genetic mutations?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following:

  • Diagnosed prevalent cases of ACHM by mutation status.

Note: Coverage may vary by country.

Table of contents

  • Achromatopsia - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
      • Diagnosed Prevalence of Achromatopsia per 100,000 People of All Ages in 2019 and 2029
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Achromatopsia over the Next Ten Years
      • Analysis of the Diagnosed Prevalent Cases of Achromatopsia in 2019 by Mutation Status
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases of Achromatopsia
      • Diagnosed Prevalent Cases of Achromatopsia by Mutation Status
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Achromatopsia
        • Studies Excluded from the Analysis of Achromatopsia
      • Risk/Protective Factors
        • Risk/Protective Factors for Achromatopsia
      • Bibliography

Author(s): T.J. Arndt, MPH, CPH; Nicole Zhang, MPH

T.J. joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia.

T.J. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a B.S. in Microbiology & Cell Science and a B.A. in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders.

She holds an M.P.H. from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a B.A. in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.